WASHINGTON, DC (February 21 2023) — The Association for Accessible Medicines (AAM) is pleased to announce its 2023 Associate Members. Associate Members are entities allied with the interests, needs and policy positions of generic and biosimilar medicine developers. Generic drugs saved the U.S. health system $373 billion in 2021, according to AAM’s 2022 U.S. Generic and Biosimilar Medicines Savings Report.
The 2023 Associate Members include:
ACIC Pharmaceuticals
Antheia
A-S Medication Solutions, LLC
Catholic Medical Mission Board, Inc. (CMMB)
ChemWerth Inc.
Direct Relief
Dispensary of Hope
Gedeon Richter USA
Inmar
Lachman Consultant Services, Inc.
Operation Smile
A complete list of 2023 AAM Members can be found here.
MEDIA CONTACT:
Susan Reilly
Director of Communications, AAM
1.703.725.0729
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 91 percent of prescriptions dispensed in the U.S. but only 18 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.